HFSA 2019 Annual Scientific Meeting

The Heart Failure Society of America has released the 23rd HFSA Annual Scientific Meeting Advance Program. Taking place September 13-16, 2019, the HFSA Annual Scientific Meeting offers heart failure professionals the opportunity to advance their understanding and knowledge of heart failure with a robust, multidisciplinary program.

Topics/Speaker:

1. PM 1 – Excellence in Translational Science
2. SAT 1 – Mitral Regurgitation in Heart Failure 2019 Challenges and Opportunities
3. SAT 2 – Cardiovascular, Metabolic, and Renal Outcomes in Multi-Morbid Heart Failure Patients with Type 2 Diabetes
4. SAT 3 – Improving Outcomes in Your HF Patients with Evidence-Based Treatment of Hyperkalemia
5. PLENARY – Independence from Heart Failure Awareness, Empathy and Activism
6. SESSION 1 – Acute Cardiogenic Shock to Recovery STEMI, Myocarditis, and Acute Insults
7. SESSION 2 – Great Debates and Current Controversies Across the Atlantic
8. SESSION 3 – Ten Simple Tips How to Prevent HF
9. SESSION 4 – Prognosis and Treatments for Ambulatory Advanced HF
10. SESSION 5 – General Cardiology vs Community and Academic HF – Let’s Learn from Each Other
11. SESSION 6 – Ten Simple Tips Management of Complexities in Cardiogenic Shock
12. SESSION 7 – Rapid Fire Abstracts for Original Investigations
13. SESSION 8 – Challenges in Managing Adult Congenital Heart Disease PH, RV Failure, Arrhythmia
14. SESSION 9 – Change is Inevitable Impact of Nursing and Allied Health Amongst the Medical Circulatory Support World
15. SESSION 10 – FDA Special Session Focusing on Patient in Clinical Research and Drug Development
16. SAT 4 – Symptoms are the Tip of the Iceberg Navigating Management of Congestion in Heart Failure
17. SAT 5 – Team Based Approach to Combined Medical and Surgical Management of Advanced Heart Failure Optimal Use and Impact of Mechanical Circulatory Support
18. SESSION 11 – Ten Simple Tips Identifying the Ever-Elusive Volume Overload in the Clinic
19. SESSION 12 – 2019 Update on Clinical Trials for Emerging HF Drugs and Device Therapies
20. SESSION 13 – Defining RV Failure Pathophysiology and Clinical Perspectives
21. SESSION 14 – JNC Investigator Award Basic Science & Clinical
22. SESSION 15 – Nursing Investigator Award Research & Clinical1
23. SESSION 16 – Ten Simple Tips How to Best Implement Technologies to Assist in HF Care and Reduce Readmissions
24. SESSION 17 – Systemic Pathway Dysregulation in HFpEF How Mechanisms Enlighten Clinical Approaches
25. Session 18 – HF in End-Stage Kidney Disease A Multidisciplinary Approach to an Underestimated Problem1
26. SESSION 19 – Contemporary Dilemmas in LVAD Therapy
27. SESSION 20 – Fundamental skills for AHFTC Training
28. SESSION 22 – Systems of care in Cardiogenic Shock
29. 2018-2019 Top Ten Trials, News & Publication in HF
30. SESSION 26 – Payer Mandates for Formal Shared Decision-Making How do I Meet Coverage Decision Mandates
31. SESSION 23 – Translational Omics in Heart Failure Finally Getting Clinical
32. SESSION 25 – Lessons Learned 100 Years from HF Nurses
33. SESSION 27 – International Session Global Challenges and Best Practices in Acute HF
34. SESSION 28 – How to Diagnose and Manage Inflammatory Cardiomyopathies Myocarditis Foundation
35. Diet, Nutrition & Cardiac Function – From Beside to Bench & Back Again
36. SESSION 30 – Clinical Conundrums Pharmacotherapy for HFrEF Case-Based Debates
37. SESSION 31 – How to Engage Patient-Caregiver Dyads in Managing HF
38. SAT 6 – Reducing Cardiovascular and Renal Risk with SGLT2 Inhibitors Exploring Evidence
39. SAT 7 – Brave New World of ATTR Cardiac Amyloidosis Avoiding Pitfalls in Diagnosis and Treatment
40. SESSION 34 – Ten Simple Tips Cardiac Amyloidosis – No Longer an Academic Exercise, Now a Treatable Pandemic
41. Controversies in Acute Cardio-Renal Syndrome – Discussion & Debates on Fluid Wars
42. SESSION 35 – How to Manage Cardiovascular Complications during Pregnancy
43. Clinical Conundrums – Managing AFib & Device Therapies in HF – Case-Based Debates
44. SESSION 37 – Advocacy Committee The Multidimensional Challenge of Drug Pricing and Preapprovals
45. SESSION 39 – The Spectrum of Care for Patients with Genetic Cardiomyopathies
46. SESSION 38 – Late Breaking Clinical Trials
47. SESSION 40 – Ten Simple Tips Management of Patients with Diabetes and HF
48. SESSION 41 – Functional Mitral Regurgitation An Update on Treatment Strategies
49. SESSION 42 – Barriers to Implementation of New Therapies
50. SESSION 53 – Late Breaking Clinical Trials and Insights with Angiotensin Receptor Neprilysn Inhibitors
51. SESSION 43 – Ten Simple Tips How to Best Treat Volume Overload in Acute HF
52. SESSION 44 – New Insights in Cardio-Oncology
53. SESSION 45 – Understanding the Heart-Brain Connection New Insights in Cognitive Impairment and Sleep-Disordered Breathing
54. SESSION 46 – The New Heart Transplantation Allocation
55. SESSION 47 – Pharmacist-Driven Transition of Care and Optimization Clinics
56. SESSION 54 – HF Awareness in African Americans
57. SESSION 48 – HYDE PARK
58. SESSION 49 – Addressing the Recovered Ejection Fraction Is It Still Heart Failure
59. SESSION 50 – Ten Simple Tips Managing Patients Across the Spectrum of Pulmonary Hypertension
60. SESSION 51 – The Psychosocial Assessment of the Advanced HF Patient
61. SESSION 52 – Learning Health Systems, Real World Evidence and HF Hype or Reality